Purpose: To evaluate the short-term efficacy of intravitreal anti-VEGF (Lucentis) and sub-tenon injection of triamcinolone acetonide for choroidal neovascularization (CNV) associated with multifocal choroiditis
Introduction
Multifocal choroiditis (MC) is a relatively uncommon idiopathic chorioretinitis which was firstly reported by Nozik and Dorsch Eli in 1973 [1] . It is characterized in most cases by multiple punched-out choroidal spots in association with signs of vitreous and anterior chamber inflammation [2] [3] . Visual acuity impairment may depend on several causes including cystoid macular edema, CNV and scarring of the fovea. The occurrence of CNV is the most frequent cause of visual loss [4] [5] . There are no proven methods of treating CNV associated with MC. Recent studies showed that sub-tenon injection of corticosteroids has been successful in causing regression of CNV in some patients. However, many patients still have CNV after corticosteroids treatment alone. Anti-VEGF treatment has been showed to be effective in destroying CNV with almost no injury to the retina [6] . In this article, we retrospectivey reviewed the efficacy of combined intravitreal anti-VEGF and sub-tenon injection of TA in treating CNV in 7 patients with MC at our clinic.
Patients and Methods

Patients
We retrospectively reviewed the medical records of 8 eyes of 8 MC patients, who Exclusion criteria were: 1) severe refracting media opacity complications such as severe cataract, keratopathy, vitreous hemorrhage which will affect ocular fundus examination and treatment; 2) severe hypertension, diabetes mellitus and impaired cardiac, pulmonary and renal function; 3) tuberculosis infection.
The potential risks and benefits were discussed with all patients before they received treatment, and each patient read and signed an informed consent form.
Combination Therapy
After intravitreal lucentis (0.05 ml, 0.5 mg) injection, 2 ml TA (50 mg/5 ml) was delivered via sub-tenon injection after routine sterilization and topical anesthesia. All the patients had only one session combination therapy.
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at baseline and 3, 6 months after treatment. Ocular anterior segment/fundus examinations as well as FFA/ICGA and OCT were also performed at baseline and 3, 6 months after treatment.
Statistical Analysis
The BCVA was performed statistical analysis (ANOVA) using SPSS 11.5 (SPSS, Inc., Chicago, IL). P < 0.05 was considered as statistically significant.
Results
BCVA and Ocular Anterior Segment/Fundus Examination
The mean BCVA was 0.06 ± 0.02, 0.38 ± 0.11 and 0.42 ± 0.09 before and 3, 6 months after treatment. BCVA at 3 and 6 months after treatment had significantly improved compared with baseline (P < 0.05) while the differences of BCVA between 3 and 6 months was not significant (P > 0.05). 
Adverse Events
There were no serious treatment-related adverse events in all patients expect 1 complaining of slight eye pain during which disappeared right after the administration. There were no systemic adverse events.
Discussion
MC is a kind of chronic and recurrent chorioretinitis. The typical fundus examination shows there are scattered grey-yellow lesions situated in the posterior pole or mid-periphery. About 1/3 of the patients with MC have CNV. The neovascularization associated exudation and bleeding will lead to RPE or neuroretinal detachment and finally disc-scar formation [7] .
The cause of MC is not clearly understood. It is reported to be associated with viral infection, or other infection diseases such as tuberculosis or syphilis [8] . There is no proven therapy for MC. The common treatment modality such as immunosuppressive agents and corticosteroids can be successful in treating inflammation of MC with limited efficacy in associated CNV [9] . Current therapies for CNV include laser photocoagulation, surgery, PDT and intravitreal anti-VEGF. Both laser photocoagulation and PDT can cause severe vision loss in subfoveal CNV and recurrence of CNV is common [10] . Surgery did not increase the chance of stable of improved visual acuity, and was associated with a high risk of rhegmatogenous retinal detachment.
After introduction of anti-VEGF agents, many investigators have reported the efficacy of anti-VEGF monotherapy or combined therapy with PDT for exudative AMD [11] [12] [13] [14] .
In this study, we evaluated one session of intravitreal lucentis combined with posterior sub-tenon injection of TA for CNV secondary to MC. We found that during the 6-month follow up, all the patients treated had significant improvement of BCVA. FFA/ICGA showed stoppage or decrease of anterior and fundus inflammation as well as leakage from CNV. OCT showed reduced CNV area and The present study has important limitations including its retrospective nature, small sample size, short follow-up time and lack of a control group. However, the positive results of the study and the absence of treatment-related side effects suggest that intravitreal anti-VEGF combined with sub-tenon injection of TA may be considered as a safe and effective treatment option for CNV secondary to MC for a 6-month period. Further studies are necessary to confirm the preliminary results and to improve current treatment modalities.
Conclusion
Here, we presented the case reports of combined therapy for patients with CNV secondary to MC. Although the follow-up time and the number of patients in this study were limited, the use of intravitreal anti-VEGF combined with subtenon injection of TA was associated with improvement of visual acuity in patients with CNV secondary to MC. Further studies including a greater number of patients with longer follow up time are needed.
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